1.Comparison of clinical efficacy of orthotopic ileal neobladder versus orthotopic sigmoid neobladder
Jian-Song WANG ; Hong-Yi XU ; Yong-Fu SHI ; Hui ZHAN ; Jong-Ming LI ; Ze-Hui LI ; Yi-Gang ZUO ; Delin YANG ; Chao WANG ; Chang-xing KE ; Ming-xia DING ; Ru-ping YAN
Chinese Journal of Urology 2000;0(12):-
Objective To compare the clinical efficacy of orthotopic ileal neobladder versus ortho- topic sigmoid neobladder.Methods The data of 96 patients who had undergone orthotopic ileal neoblad- der and 68 patients who had undergone orthotopic sigmoid neobladder were retrospectively analyzed.The perioperative condition,urinary continence,urodynamics,and pouch-related complications were compared between the 2 groups.Results Of all the 164 patients,12(7.3%)were lost to follow-up.The mean fol- low-up was 46(2-86)months in orthotopic ileal neobladder group,and 42(4-78)months in orthotopic sigmoid neobladder group.There was no significant difference in intraoperative blood loss and postoperative urinary continence between the 2 approaches(P>0.05).However,compared with sigmoid neobladder group,ileal neobladder group had longer operative time and postoperative recovery time,and got a bigger pouch(P<0.05).The early and late pouch-related complication rates of ileal neohladder group were 16. 7% and 29.2%,which were higher than those of sigmoid neobladder group.During the follow-up,tumor recurred in 3 cases of ileal neobladder group,but none in sigmoid neobladder group.Conclusions Ortho- topic ileal neobladder and sigmoid neobladder are similar in operative difficulties,and both can achieve satis- factory clinical results.Compared with ileal neobladder,sigmoid neobladder has shorter operative time, quicker recovery and lower rate of pouch-related complications,thus is a preferred procedure.
2.Bioactivity assay of bupleurum injection for inhibiting PGE2 release in vitro.
Ze-Ping ZUO ; Zhi-Bin WANG ; Yang GAO ; Yu-Dong GUO ; Bi-Song WANG ; Bin SU ; Cheng-Cheng SONG
China Journal of Chinese Materia Medica 2013;38(22):3957-3960
OBJECTIVETo establish the in vitro model of PGE2 released by hypothalamic neurocytes under rrIL-1beta in vitro interference, and investigate the correlation of the PGE2 content and the effect of the drug effect concentration in the model under the effect of Bupleurum injection.
METHODHypothalamic neurocytes were cultured in vitro, and added with rrIL-1beta (40 microg x L(-1)) stimulation. Cell sap was collected at different time points. ELISA was adopted to determine the content of PGE2 in cell sap collected at different time points. Hypothalamic neurocytes were cultured in vitro, added with rrIL-1beta (40 microg x L(-1)) stimulation and then different concentrations of Bupleurum injection. The changes in the content of PGE2 in cell supernatant were detected by ELISA. An analysis was made on the linear relationship between the sample concentration and the inhibition rate of PGE2.
RESULTThe rrIL-1 cells could stimulate in vitro cultured hypothalamic neurocytes to release PGE2 and reach the peak at 10 h. Bupleurum injection could significantly interfere the release of PGE2 in the in vitro model (P < 0.01, P < 0.05), with a certain linear relationship between the interference effect and the effect concentration of Bupleurum injection (r = 0.911, P < 0.01).
CONCLUSIONThe rrIL-1 cells could stimulate in vitro cultured hypothalamic neurocytes to release PGE2, with a good correlation between the inhibition and generation effects of PGE2 and the drug concentration.
Animals ; Biological Assay ; Bupleurum ; chemistry ; Cells, Cultured ; Dinoprostone ; metabolism ; Drugs, Chinese Herbal ; pharmacology ; Female ; Hypothalamus ; cytology ; drug effects ; metabolism ; Neurons ; drug effects ; metabolism ; Rats ; Rats, Sprague-Dawley
3.Bioassay method for Compound Danshen Tablets based on a platelet aggregation inhibition test
Yu-dong GUO ; Yu-chi HU ; Cun-ran CAO ; Zhi-bin WANG ; Ze-ping ZUO ; Yang GAO ; Tan-yu LOU ; Bei-bei MA
Acta Pharmaceutica Sinica 2019;54(12):2184-2188
A bioassay method for inhibiting platelet aggregation
4.Morin induces autophagy and apoptosis in hepatocellular carcinoma cells through Akt/mTOR/STAT3 pathway.
Xin-Yue ZHAO ; Ying-Ying TIAN ; Chuang LIU ; Yi-Lin LI ; Ying-Nan LYU ; Shang-Yue YU ; Shi-Qiu TIAN ; Hai-Luan PEI ; Ze-Ping ZUO ; Zhi-Bin WANG
China Journal of Chinese Materia Medica 2023;48(16):4475-4482
This study investigated the effect and mechanism of morin in inducing autophagy and apoptosis in hepatocellular carcinoma cells through the protein kinase B(Akt)/mammalian target of rapamycin(mTOR)/signal transducer and activator of transcription protein 3(STAT3) pathway. Human hepatocellular carcinoma SK-HEP-1 cells were stimulated with different concentrations of morin(0, 50, 100, 125, 200, and 250 μmol·L~(-1)). The effect of morin on the viability of SK-HEP-1 cells was detected by Cell Counting Kit-8(CCK-8). The effect of morin on the proliferation and apoptosis of SK-HEP-1 cells was investigated using colony formation assay, flow cytometry, and BeyoClick~(TM) EdU-488 with different concentrations of morin(0, 125, and 250 μmol·L~(-1)). The changes in the autophagy level of cells treated with morin were examined by transmission electron microscopy and autophagy inhibitors. The impact of morin on the expression levels of proteins related to the Akt/mTOR/STAT3 pathway was verified by Western blot. Compared with the control group, the morin groups showed decreased viability of SK-HEP-1 cells in a time-and concentration-dependent manner, increased number of apoptotic cells, up-regulated expression level of apoptosis marker PARP, up-regulated phosphorylation level of apoptosis-regulating protein H2AX, decreased number of positive cells and the colony formation rate, an upward trend of expression levels of autophagy-related proteins LC3-Ⅱ, Atg5, and Atg7, and decreased phosphorylation levels of Akt, mTOR, and STAT3. These results suggest that morin can promote apoptosis, inhibit proliferation, and induce autophagy in hepatocellular carcinoma cells, and its mechanism of action may be related to the Akt/mTOR/STAT3 pathway.
Humans
;
Proto-Oncogene Proteins c-akt/metabolism*
;
Carcinoma, Hepatocellular/pathology*
;
Liver Neoplasms/pathology*
;
TOR Serine-Threonine Kinases/metabolism*
;
Apoptosis
;
Autophagy
;
Cell Proliferation
;
Cell Line, Tumor
;
STAT3 Transcription Factor/metabolism*
5.Inhibitory effect and molecular mechanism of sinomenine on human hepatocellular carcinoma HepG2 and SK-HEP-1 cells.
Ying-Ying TIAN ; Bei-Bei MA ; Xin-Yue ZHAO ; Chuang LIU ; Yi-Lin LI ; Shang-Yue YU ; Shi-Qiu TIAN ; Hai-Luan PEI ; Ying-Nan LYU ; Ze-Ping ZUO ; Zhi-Bin WANG
China Journal of Chinese Materia Medica 2023;48(17):4702-4710
This study aimed to investigate the effect and molecular mechanism of sinomenine on proliferation, apoptosis, metastasis, and combination with inhibitors in human hepatocellular carcinoma HepG2 cells and SK-HEP-1 cells. The effect of sinomenine on the growth ability of HepG2 and SK-HEP-1 cells were investigated by CCK-8 assay, colony formation assay, and BeyoClick~(TM) EdU-488 staining. The effect of sinomenine on DNA damage was detected by immunofluorescence assay, and the effect of sinomenine on apoptosis of human hepatocellular carcinoma cells was clarified by Hoechst 33258 staining and CellEvent~(TM) Cystein-3/7Green ReadyProbes~(TM) reagent assay. Cell invasion assay and 3D tumor cell spheroid invasion assay were performed to investigate the effect of sinomenine on the invasion ability of human hepatocellular carcinoma cells in vitro. The effect of sinomenine on the regulation of protein expression related to the protein kinase B(Akt)/mammalian target of rapamycin(mTOR)/signal transducer and activator of transcription 3(STAT3) signaling pathway in HepG2 and SK-HEP-1 cells was examined by Western blot. Molecular docking was used to evaluate the strength of affinity of sinomenine to the target cysteinyl aspartate specific proteinase-3(caspase-3) and STAT3, and combined with CCK-8 assay to detect the changes in cell viability after combination with STAT3 inhibitor JSI-124 in combination with CCK-8 assay. The results showed that sinomenine could significantly reduce the cell viability of human hepatocellular carcinoma cells in a concentration-and time-dependent manner, significantly inhibit the clonogenic ability of human hepatocellular carcinoma cells, and weaken the invasive ability of human hepatocellular carcinoma cells in vitro. In addition, sinomenine could up-regulate the cleaved level of poly ADP-ribose polymerase(PARP), a marker of apoptosis, and down-regulate the protein levels of p-Akt, p-mTOR, and p-STAT3 in human hepatocellular carcinoma cells. Molecular docking results showed that sinomenine had good affinity with the targets caspase-3 and STAT3, and the sensitivity of sinomenine to hepatocellular carcinoma cells was diminished after STAT3 was inhibited. Therefore, sinomenine can inhibit the proliferation and invasion of human hepatocellular carcinoma cells and induce apoptosis, and the mechanism may be attributed to the activation of caspase-3 signaling and inhibition of the Akt/mTOR/STAT3 pathway. This study can provide a new reference for the in-depth research and clinical application of sinomenine and is of great significance to further promote the scientific development and utilization of sinomenine.
Humans
;
Carcinoma, Hepatocellular/genetics*
;
Proto-Oncogene Proteins c-akt/metabolism*
;
Caspase 3/metabolism*
;
Liver Neoplasms/genetics*
;
Molecular Docking Simulation
;
Sincalide/pharmacology*
;
Cell Line, Tumor
;
Cell Proliferation
;
Hep G2 Cells
;
TOR Serine-Threonine Kinases/metabolism*
;
Apoptosis